undamentalytics Newsletter
Sign in

DBV Technologies S.a. revenue

DBV Technologies S.a.'s revenue was $5.6m in fiscal 2025, up 35.8% on the year before. Since fiscal 2019 ($14.7m) it has grown at a compound -14.8% a year. Over the last twelve months it was $3.8m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue15116516464
Growth on the year before—−23.3%−49.4%−15.1%+224.7%−73.6%+35.8%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
DBV Technologies S.a. $3.8m -31.6% -11.6%
Dyadic International Inc $3.8m -8.0% 3.4%
Aligos Therapeutics, Inc. $3.7m 19.4% -5.5%
Camp4 Therapeutics Corp $4.2m 40.2% —
Curis Inc $4.3m -62.2% -25.0%
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%

Compare with peers

Head to head: DBVT vs DYAIALGS vs DBVTCAMP vs DBVT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from DBV Technologies S.a.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to DBV Technologies S.a.